Moderna, Inc. Increase (Decrease) in Income Taxes Payable
Moderna, Inc. (MRNA) reported Increase (Decrease) in Income Taxes Payable of -$58.00 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2024-11-07
- Moderna, Inc. increase (decrease) in income taxes payable for the quarter ending 2024-09-30 was -$2.00M, a 122.22% decline year-over-year.
- Moderna, Inc. increase (decrease) in income taxes payable for the quarter ending 2024-06-30 was -$45.00M.
- Moderna, Inc. increase (decrease) in income taxes payable for the quarter ending 2024-03-31 was -$11.00M, a 161.11% decline year-over-year.
- Moderna, Inc. increase (decrease) in income taxes payable for the quarter ending 2023-12-31 was $7.00M.
- Moderna, Inc. increase (decrease) in income taxes payable for fiscal 2023 was $15.00M.
- Moderna, Inc. increase (decrease) in income taxes payable for fiscal 2022 was -$828.00M, a 194.52% decline from fiscal 2021.
- Moderna, Inc. increase (decrease) in income taxes payable for fiscal 2021 was $876.00M.
- Moderna, Inc. increase (decrease) in income taxes payable for fiscal 2020 was $0.00.
| Period end | Increase (Decrease) in Income Taxes Payable 3 month | Increase (Decrease) in Income Taxes Payable 6 month | Increase (Decrease) in Income Taxes Payable 9 month | Increase (Decrease) in Income Taxes Payable 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$47.00M derived: sum of 2 quarters · filed 2024-11-07 | -$58.00M 10-Q · filed 2024-11-07 | -$51.00M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | -$45.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$56.00M 10-Q · filed 2024-08-01 | -$49.00M derived: sum of 3 quarters · filed 2024-08-01 | -$40.00M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | -$11.00M 10-Q · filed 2024-05-02 | -$4.00M derived: sum of 2 quarters · filed 2024-05-02 | $5.00M derived: sum of 3 quarters · filed 2024-11-07 | -$14.00M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $16.00M derived: sum of 2 quarters · filed 2024-11-07 | -$3.00M derived: sum of 3 quarters · filed 2024-11-07 | $15.00M 10-K · filed 2024-02-23 |
| 2023-09-30 | $9.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$10.00M derived: sum of 2 quarters · filed 2024-11-07 | $8.00M 10-Q · filed 2024-11-07 | -$10.00M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$19.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$1.00M 10-Q · filed 2024-08-01 | -$19.00M derived: sum of 3 quarters · filed 2024-08-01 | -$302.00M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $18.00M 10-Q · filed 2024-05-02 | $0.00 derived: sum of 2 quarters · filed 2024-05-02 | -$283.00M derived: sum of 3 quarters · filed 2024-05-02 | -$1.53B derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | -$18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | -$301.00M derived: sum of 2 quarters · filed 2024-02-23 | -$1.54B derived: sum of 3 quarters · filed 2024-02-23 | -$828.00M 10-K · filed 2024-02-23 |
| 2022-09-30 | -$283.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$1.53B derived: sum of 2 quarters · filed 2023-11-03 | -$810.00M 10-Q · filed 2023-11-03 | -$499.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-06-30 | -$1.24B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$527.00M 10-Q · filed 2023-08-03 | -$216.00M derived: sum of 3 quarters · filed 2024-02-23 | -$28.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-03-31 | $716.00M 10-Q · filed 2023-05-04 | $1.03B derived: sum of 2 quarters · filed 2024-02-23 | $1.22B derived: sum of 3 quarters · filed 2024-02-23 | $1.50B derived: sum of 4 quarters · filed 2024-02-23 |
| 2021-12-31 | $311.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $499.00M derived: sum of 2 quarters · filed 2024-02-23 | $786.00M derived: sum of 3 quarters · filed 2024-02-23 | $876.00M 10-K · filed 2024-02-23 |
| 2021-09-30 | $188.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $475.00M derived: sum of 2 quarters · filed 2022-11-03 | $565.00M 10-Q · filed 2022-11-03 | $565.00M derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-06-30 | $287.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $377.00M 10-Q · filed 2022-08-03 | $377.00M derived: sum of 3 quarters · filed 2023-02-24 | |
| 2021-03-31 | $90.00M 10-Q · filed 2022-05-04 | $90.00M derived: sum of 2 quarters · filed 2023-02-24 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $0.00 10-K · filed 2023-02-24 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |